Bal Pharma, Akaal Pharma to develop novel veterinary therapeutics

07 Mar 2018 Evaluate

Bal Pharma has entered into collaboration with Akaal Pharma, Melbourne, Australia whereby both companies have launched a Joint Venture Company (JVC) - AB VET Pharma. The new joint venture will be completely funded by Bal Pharma to develop Akaal Pharma’s IP within the veterinary field.

The first veterinary indication will be against atopic dermatitis (AD) in dogs. Akaal’s ABV-119 is the first of its kind oral drug candidate for the treatment of AD in dogs. ABV-119 is a multimodal therapy that includes anti-inflammatory/ immune modulatory and anti-itch effects. AB VET plans to begin clinical development in H1 2018.

Bal Pharma is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.


Bal Pharma Share Price

107.51 -1.11 (-1.02%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...